Status:
UNKNOWN
Role of Combined Therapy of Propranolol and Gabapentin in Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury
Lead Sponsor:
Zagazig University
Conditions:
Traumatic Brain Injury
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Paroxysmal sympathetic hyperactivity (PSH) is a syndrome that comprises a series of signs and symptoms reflecting exacerbated sympathetic activity, including arterial hypertension, fever, tachycardia,...
Detailed Description
Traumatic brain injury (TBI) is a critical public health problem worldwide. It has been referred to as the " silent epidemic " as the problems experienced by those patients (such as impairments in mem...
Eligibility Criteria
Inclusion
- • ICU patients with moderate (GCS 9-12) to severe (GCS \<9) traumatic brain injury .
Exclusion
- Pre-existing brain dysfunction .
- History of allergy to any of the combined drug therapy ( propranolol or gabapentine ) .
- History of obstructive lung disease .
- History of heart disease .
- Hypotension at admission of ICU.
- Bradycardia .
- Hypertension
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2023
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT05427474
Start Date
December 1 2022
End Date
October 31 2023
Last Update
June 13 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University Hospitals
Zagazig, Egypt, 055
2
Zagazig University
Zagazig, Egypt, 055